Pharmaceutical giant AstraZeneca ... for new and more advanced cancer medications to be launched as well. One of the company’s key drugs, Enhertu is used to treat breast cancer as well as ...

Breast cancer is the most diagnosed cancer worldwide ... Enhertu; Daiichi Sankyo/AstraZeneca), neratinib (Nerlynx; Puma), margetuximab (Margenza; MacroGenics) and tucatinib (Tukysa; Pfizer).

It said that AstraZeneca's Tagrisso infringed patents related to the breast-cancer drug Nerlynx, which Puma Biotechnology (PBYI.O), opens new tab makes with a license to Pfizer's patents.

It said that AstraZeneca's Tagrisso infringed patents related to the breast-cancer drug Nerlynx, which Puma Biotechnology makes with a license to Pfizer's patents. Advt Tagrisso earned UK-based ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

An antibody-drug conjugate, ENHERTU is developed by Daiichi Sankyo and co-commercialised with AstraZeneca. It targets HER2, a protein associated with aggressive breast cancer. The FDA granted the ...

PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes ...

AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth ... for four cancer types such as ovarian, breast, prostate and pancreatic.

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs sets ...